Sold as Cardrase, Ethamide. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Ethoxzolamide (sold as Cardrase, Ethamide), first approved Oct 12, 1966, with 0 new uses approved and 0 published complete response letters.
| Oct 12, 1966 | EthamideNDA 16144 · New formulation or manufacturer | Allergan | 5 | Discontinued |
| — | CardraseNDA 11047 | Pharmacia And Upjohn | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Allergan